secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2023-09-19T23:59:59+00:00
Accession:  0001437749-23-026258
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic signs exclusive license deal with INZYMES for dairy enzymes; $0.6M upfront
--------------------------------------------------------------------------------

- Dyadic receives $0.6M upfront for development and licensing of Dapibus platform to INZYMES.
- Exclusive license targets non-animal dairy enzymes used in food production.
- Potential success fees, milestones, and royalties beyond upfront payment.
- Addressable alternative protein market cited at >$60B, growing to $190B by 2028.
- Deal builds on previous success producing animal-free casein proteins.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923026258/0001437749-23-026258-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923026258/dyai20230918_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-026258

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer